3m Innovative Properties Company

Coley Pharmaceutical Group, Inc.

Graceway Pharmaceuticals, LLC

Other

Minnesota Mining and Manufacturing Company

Solventum Intellectual Properties Company

Bryon A Merrill

Kyle J Lindstrom

Philip D Heppner

Michael J Rice

Stephen L Crooks

George W Griesgraber

John F Gerster

John W Mickelson

Tushar A Kshirsagar

Chad A Haraldson

Gregory J Marszalek

Joseph F Dellaria, Jr

Shri Niwas

Joshua R Wurst

Peter V Maye

Matthew R Radmer

Michael E Danielson

Gregory D Lundquist, Jr

David S Hays

Patrick L Coleman

Ralph R Roberts

Ai-Ping Wei

Sarah J Slania

Karl J Manske

Leslie J Charles

Maureen Ann Kavanagh

David T Amos

Sarah A Strong

Ryan B Prince

Jason D Bonk

Scott E Langer

Hugues M H Martin

William H Moser

Kevin Jon Bechtold

David J Squire

Phillip D Heppner

Paul D Wightman

Sarah C Johannessen

Sarah C Slania

Sarah Johannessen

Hugues Martin

Imidazo[4,5-c]quinoline compounds having a substituent that is attached at the N−1 position by a branched group, single enantiomers of the compounds, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in humans and animals, and in the treatment of diseases including infectious and neoplastic diseases are also disclosed.

N-1 branched alkyl ether substituted imidazo[4,5-c]quinoline compounds, compositions, and methods

Imidazo[4,5-c] ring compounds of formula I, (particularly imidazo4,5-c]quinolines, 6,7,8,9-tetrahydroimidazo[4,5-c]quinolines, imidazo[4,5-c]naphthyridines, and 6,7,8,9-tetrahydroimidazo[4,5-c]naphthyridine compounds) having a guanidine substituted benzamide that is attached at the N&#x2212;1 position by a linking group, pharmaceutical compositions containing the compounds, and methods of making the compounds are disclosed. Methods of use of the compounds as immune response modifiers, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are also disclosed. 

Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups

Imidazoquinoline compounds with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of use of these compounds as immunomodulators, for inducing or inhibiting cytokine biosynthesis in animals and in the treatment of diseases including viral, and neoplastic, are disclosed.

Alkoxy substituted imidazoquinolines

Thiazoloquinolines and thiazolonaphthyridines with an alkoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines

A method of preferentially inducing IFN-&#x3b1; biosynthesis in an animal comprising administering certain imidazo[4,5-c] ring compounds with a hydroxymethyl or hydroxyethyl substituent at the 2-position or pharmaceutical compositions containing the compounds, intermediates, methods of making, and methods of using these compounds a immunomodulators for treatment of diseases including viral and neoplastic diseases comprising preferentially inducing IFN-&#x3b1; biosynthesis in an animal are disclosed.

Method of preferentially inducing the biosynthesis of interferon

Imidazoquinolines and imidazonaphthyridines with a substituent containing a functional group, e.g., an amide, sulfonamide, urea, or heterocyclyl group, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Substituted imidazoquinolines and imidazonaphthyridines

Amide and carbamate derivatives N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide, pharmaceutical compositions containing these compounds, methods of making the compounds, and methods of use of these compounds in modulating the immune system, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Amide and carbamate derivatives of N-{2-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-dimethylethyl}methanesulfonamide and methods

Imidazoquinoline compounds with an aryloxy or arylalkyleneoxy substituent at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, and methods of use of these compounds as immunomodulators, for modulating cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

Aryloxy and arylalkyleneoxy substituted imidazoquinolines

Amide and carbamate derivatives of N-[4-(4-amino-1H-imidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamides with an ethyl, methyl, or n-propyl substituent at the 2-position, pharmaceutical compositions containing these compounds, methods of making the compounds, and methods of use of these compounds in modulating the immune system, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases, are disclosed.

[object Object]

Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazoquinolines

Certain imidazoquinolines with a hydroxymethyl or hydroxyethyl substituent at the 2-position, and an aryl or heteroaryl substituent at the 7-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for preferentially inducing IFN-&#x3b1; biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Hydroxyalkyl substituted imidazoquinoline compounds and methods

Pyrazolo[3,4-c]quinolines, pyrazolo[4,5-c]naphthyridines, and analogs thereof, eg., 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinolines, and, pharmaceutical compositions containing the compounds, intermediates, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inhibiting cytokine biosynthesis in animals and in the therapeutic or prophylactic treatment of diseases by inhibiting cytokine biosynthesis are disclosed.

Pyrazolo[3,4-C]quinolines, pyrazolo[3,4-C]naphthyridines, analogs thereof, and methods

Fused [1,2]imidazo[4,5-c] ring compounds, e.g., fused [1,2]imidazo[4,5-c]quinolines and [1,2]imidazo[4,5-c]naphthyridines, with a substituent, e.g., a substituted alkoxy substituent, at the 6, 7, 8, or 9-position, pharmaceutical compositions containing the compounds, intermediates, methods of making and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed.

Substituted fused [1,2]imidazo[4,5-C] ring compounds and methods

Growing community of inventors

River Falls, WI, United States of America

Bryon A Merrill